INVESTIGATIONS OF THE INFLUENCE OF SUFAN ON MYOCARDIAL METABOLISM IN CASES OF EXPERIMENTAL HEART FAILURE

This article presents the results of an influence by the new non-glycoside structure, metabolic cardiotonic drug “sufan” on the energetic metabolism and oxidative homeostasis indicators—in myocardium, brain, and spleen of intact rats and rats with adriamycin-induced heart failure. It was established that sufan increased the coefficient of oxidative/reduced forms of nicotinamide coenzymes, reduced the adriamycin, causing deterioration of the energetic metabolism and the pro-oxidative-anti-oxidative homeostasis. The use of the non-glycoside structure cardiotonic drug, sufan, is recommended in order to prevent cardiotoxic effects of the anthracycline antibiotics.